Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.

(2017) J. S. Kauh et al.   JOURNAL OF CLINICAL ONCOLOGY

MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study.

(2017) S. Bhatia et al.   JOURNAL OF CLINICAL ONCOLOGY

Applications of Pathology-Assisted Image Analysis of Immunohistochemistry-Based Biomarkers in Oncology

(2013) V. Shinde et al.   VETERINARY PATHOLOGY

Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924

(2012) Michael A. Milhollen et al.   CANCER CELL

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

(2011) D. E. Reece et al.   BLOOD

Inhibition of NEDD8-Activating Enzyme Induces Rereplication and Apoptosis in Human Tumor Cells Consistent with Deregulating CDT1 Turnover

(2011) M. A. Milhollen et al.   CANCER RESEARCH

Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer

(2011) Meng Wang et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma

(2010) M. A. Milhollen et al.   BLOOD

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia

(2010) R. T. Swords et al.   BLOOD

NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer Cells

(2010) J. J. Lin et al.   CANCER RESEARCH

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ

(2010) James E. Brownell et al.   MOLECULAR CELL

The ubiquitous nature of cancer: the role of the SCFFbw7 complex in development and transformation

(2010) K M Crusio et al.   ONCOGENE

Cul1 expression is increased in early stages of human melanoma

(2010) Guangdi Chen et al.   Pigment Cell & Melanoma Research

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

(2009) Alan K. Burnett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer

(2009) T. A. Soucy et al.   CLINICAL CANCER RESEARCH

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

(2009) Teresa A. Soucy et al.   NATURE

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

(2008) A. Goy et al.   ANNALS OF ONCOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE